安科生物(300009.SZ):擬出資3000萬元參設合肥連山創新產業投資基金合夥企業
格隆匯11月18日丨安科生物(300009.SZ)公佈,為積極發掘具有良好成長性和發展前景的戰略性新興項目,進一步促進公司整體戰略目標的實現,公司擬與普通合夥人合肥科訊創業投資管理合夥企業(有限合夥)(“合肥科訊”),及有限合夥人田明、曹仁賢、科大訊飛股份有限公司、陳先保、三亞高卓佳音信息科技合夥企業(有限合夥)、郭子珍、魏臻、朱慶龍和吳華峯等共同出資設立合肥連山創新產業投資基金合夥企業(有限合夥)(以工商核定名稱為準)。其中公司擬以自有資金作為該基金的有限合夥人出資3000萬元人民幣,佔該基金總認繳出資額的6.00%。
合肥科訊創業投資管理合夥企業(有限合夥)作為備案的基金管理人,主要投資方向為投資及作為管理人管理中國境內外人工智能、生命科技、智能製造、新能源、新消費等科技創新相關產業方向的投資基金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.